Authors
Loading...
Preclinical studies highlight potential therapies for CMT1A, suggesting gene editing and PXT3003 may improve outcomes.
Qi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: